The expansion will bring together talent in AI, data science, and engineering to build the digital foundation needed to accelerate drug discovery and delivery
The company reported a 28% year-on-year increase in Q2 revenue to Rs. 220.9 crore
EBITDA rose to Rs. 218.1 crore, a 14.8% year-on-year increase
he new version features a streamlined sample-to-analysis workflow, built-in HRD detection, faster turnaround, and lower tissue requirements
The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results
The facility includes advanced laboratories to monitor market trends, consumer needs, product innovation, and formulation improvements
Our specialty chemical businesses have continued to perform strongly, growing double digit YoY
Trixeo is the first pMDI medicine in AstraZeneca’s portfolio to use the near-zero GWP propellant
The Genexus platform enables Next-Generation Sequencing with significantly faster turnaround times
Subscribe To Our Newsletter & Stay Updated
